We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+44.94%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.82B
AUM Growth
+$315M
Cap. Flow
-$132M
Cap. Flow %
-7.25%
Top 10 Hldgs %
68.81%
Holding
39
New
2
Increased
2
Reduced
21
Closed
2

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.44M
2
FOLD
Amicus Therapeutics
FOLD
+$2.3M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$1.37M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$449K

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$35.1M
2
ABMD
Abiomed Inc
ABMD
+$16.7M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.2M
4
UTHR icon
United Therapeutics
UTHR
+$11.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 84.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$1.54M 0.08%
29,500
– –
ALIM
27
DELISTED
Alimera Sciences
ALIM
$1.52M 0.08%
200,919
-1
-0% -$6
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.44M 0.08%
+88,590
New +$1.37M
CYTK icon
29
Cytokinetics
CYTK
$10.5B
$1.31M 0.07%
123,686
– –
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.28M 0.07%
+37,400
New +$449K
ALDX icon
31
Aldeyra Therapeutics
ALDX
$91.7M
$427K 0.02%
73,500
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$393K 0.02%
33,214
– –
MRNS
33
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$271K 0.01%
31,330
– –
NERV icon
34
Minerva Neurosciences
NERV
$187M
$258K 0.01%
4,540
– –
ACGN
35
DELISTED
Aceragen Inc
ACGN
$140K 0.01%
4,537
– –
SPHS
36
DELISTED
Sophiris Bio, Inc.
SPHS
$91K 0.01%
247,000
– –
MLNT
37
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$5K ﹤0.01%
10,137
– –
ALDR
38
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-1,861,630
Closed -$35.1M
CELG
39
DELISTED
Celgene Corp
CELG
– –
-21,883
Closed -$2.17M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q4 2019 Portfolio in Review

As of Q4 2019, Palo Alto Investors held 39 positions worth $1.82B, up 21% from $1.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Palo Alto Investors withdrew a net $132M in Q4 2019, closing 2 positions and reducing 21 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $35.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Revance Therapeutics, Inc. worth $1.44M.

  • Palo Alto Investors's largest Q4 2019 buy was Revance Therapeutics, Inc.: 88,590 shares worth $1.44M.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q4 2019, an estimated $2.44M increase.
  • Palo Alto Investors's biggest Q4 2019 reduction was Abiomed Inc, cutting an estimated $16.7M.
  • Palo Alto Investors fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $35.1M.
  • Palo Alto Investors's ten largest holdings make up 69% of its $1.82B portfolio in Q4 2019.
  • Palo Alto Investors opened 2 new positions and closed 2 in Q4 2019.
  • Palo Alto Investors's portfolio value rose 21% quarter-over-quarter to $1.82B.

Based on Palo Alto Investors's 13F filing for Q4 2019, filed 14 Feb 2020.